홈 > 시장보고서 > 의약품 > 게놈 창약

시장보고서

상품코드

1389658

마이크로바이옴 치료제 시장 규모 및 예측, 세계 및 지역 점유율, 동향, 성장 기회 분석 - 유형, 용도, 최종사용자, 지역별

Microbiome Therapeutics Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis By Type, Application, End User, and Geography

발행일: 2023년 11월 | 리서치사:

The Insight Partners | 페이지 정보: 영문 160 Pages | 배송안내 : 즉시배송

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

마이크로바이옴 치료제 시장은 2022년 3억 7,592만 달러에서 2030년 8억 1,338만 달러로 성장할 것으로 예상되며, 2022-2030년간 10.1%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 전망됩니다.

인간 마이크로바이옴은 인체와 그 주변에서 확인되는 모든 미생물과 관련 대사산물/생성물을 포함합니다. 기술의 발전으로 인해 건강 및 질병 유지에 대한 장내 미생물의 다면적인 영향을 조사할 수 있게 되었습니다. 미생물은 인간 건강에서 미생물의 광범위한 잠재력으로 인해 질병 관리를 위한 치료제로 사용될 수 있는 엄청난 잠재력을 가지고 있습니다. 마이크로바이옴 치료는 모든 중증 질환을 치료할 수 있는 큰 잠재력을 가지고 있으며, 모든 환경에서의 대인관계 변동성 및 안정성과 같은 중요한 문제를 극복하여 개인 맞춤형 치료의 목적을 달성할 수 있는 잠재적인 원천이 될 수 있습니다. 분변 미생물총 이식(FMT)이나 프로바이오틱스와 같은 외인성 미생물의 투여에 의존하는 전략은 장내 미생물 관련 질환을 관리하는 데 사용될 수 있습니다.

인간 건강 유지에 있어 장내 세균총의 잠재력, 마이크로바이옴 치료제 시장 성장 촉진

미생물 치료제는 박테리오파지, 박테리오신, 항생제, 상재균 또는 합성균 또는 감산 또는 조절 치료를 사용하여 장내 미생물을 변경하는 것을 목표로 합니다. 이 전략은 개별화, 조화, 신뢰성 및 지속 가능한 치료를 제공함으로써 기존 치료법의 한계를 극복할 수 있습니다. 세계 치료제 시장은 엄청난 경제적 잠재력을 보여주고 있습니다. 연구에 따르면 염증성 장 질환, 비만, 심지어 정신 질환과 같은 질병에 대한 마이크로바이옴 치료제의 사용에서 유망한 결과를 보여주었습니다. 현재 진행 중인 연구는 암 치료, 당뇨병 관리, 심혈관 건강 등의 분야에서 마이크로바이옴 기반 개입의 가능성을 모색하고 있습니다. 또한, 소화기 질환의 유병률은 연령에 따라 증가하고 있으며, 2021년 2월 GI 얼라이언스의 데이터에 따르면 약 2,000만 명의 미국인이 만성 소화기 질환을 앓고 있으며, 매년 6,200만 명 이상의 미국인이 소화기 질환 진단을 받고 있는 것으로 추산됩니다. 국제위장장애재단(IFFGD)은 GERD 유병률이 북미에서 18%-28%, 남미에서 23%, 유럽에서 9-26%라는 통계를 발표했습니다. 따라서 향후 몇 년동안 위장장애의 빈도 증가가 시장 확대의 원동력이 될 것으로 보입니다.

과학자들은 마이크로바이옴과 질병 발병의 복잡한 관계를 이해함으로써 단순히 증상을 관리하는 것이 아니라 문제의 근본 원인을 목표로 하는 맞춤 치료법을 개발하고 있습니다. 지식이 확대되고 기술이 발전함에 따라 마이크로바이옴 치료제는 현대 의학의 초석이 될 수 있으며, 다양한 질병을 앓고 있는 사람들의 건강 상태를 개선할 수 있는 희망을 가져다 줄 수 있습니다.

인간의 건강과 질병에 있어 마이크로바이옴의 중요성이 인식되면서 인간 마이크로바이옴을 더 잘 이해하고 마이크로바이옴 치료제를 개발하기 위한 엄격한 연구 개발이 장려되고 있습니다. 그 결과, 잠재적인 치료제를 개발하고 억제요인을 식별하는 데 도움이 되고 있습니다. 기술 및 연구 도구의 발전도 연구개발의 발전에 기여하고 있습니다. 차세대 염기서열 분석과 메타게놈 분석은 마이크로바이옴에 대한 보다 종합적이고 심층적인 연구를 가능하게 합니다. 이러한 도구를 통해 연구자들은 특정 미생물 종과 그 기능을 식별하고 미생물 군집의 시간 경과에 따른 변화를 추적할 수 있게 되었으며, FDA와 같은 규제 당국도 마이크로바이옴 치료제 분야의 연구 개발 노력을 지원하고 있다, 안전성과 유효성을 보장하는 규제 경로를 통해 이 분야를 발전시키는 데 관심을 기울이고 있습니다. 규제 당국의 이러한 지원은 기업들이 마이크로바이옴 치료제를 개발하고 시험할 수 있는 틀을 제공하고, 투자자들에게 이러한 치료제의 성공 가능성을 확신시켜줍니다. 전반적으로, 마이크로바이옴 치료제에 대한 관심 증가와 자금 조달은 연구개발의 원동력이 되고 있습니다. 이는 인간 마이크로바이옴에 대한 이해를 높이고 마이크로바이옴을 조절하여 인간의 건강을 개선할 수 있는 표적 치료제의 개발을 촉진할 것입니다.

마이크로바이옴 치료제 시장은 유형, 용도, 최종 사용자 및 지역에 따라 세분화됩니다. 마이크로바이옴 치료제 시장은 유형, 용도 및 최종 사용자에 따라 세분화됩니다. 유형별로 마이크로바이옴 치료제 시장은 치료제와 치료제로 나뉩니다. 용도별로 마이크로바이옴 치료제 시장은 대사 장애 및 비만, C. difficile 감염, 염증성 장 질환으로 분류됩니다. 최종 사용자에 따라 마이크로바이옴 치료제 시장은 병원 및 클리닉, 외래수술센터(ASC), 재택치료로 분류됩니다.

지역별로 보면 시장은 북미, 유럽, 아시아태평양, 중동 및 아프리카, 중남미로 나뉩니다. 마이크로바이옴 치료제 시장에서 북미가 가장 큰 시장 점유율을 차지하고 있습니다. 북미는 장내 세균 감염 환자 증가, 기술 발전, 장내 세균총의 중요성에 대한 인식이 높아지면서 큰 시장 점유율을 차지하고 있습니다. 건강 유지와 질병 예방에 있어 인간 마이크로바이옴의 중요성에 대한 이해도가 높아짐에 따라 미국 연구자들은 마이크로바이옴 기반 중재를 다양한 질환의 치료에 대한 유망한 접근법으로 모색하고 있습니다. 또한, 비만 및 염증성 장 질환과 같은 만성 질환의 유병률이 증가함에 따라 혁신적인 치료법에 대한 수요가 증가하면서 마이크로바이옴 치료제 개발에 박차를 가하고 있습니다. 유전자 염기서열 분석과 바이오인포매틱스의 기술 발전으로 마이크로바이옴 연구와 변형이 가능해져 개인화된 마이크로바이옴 기반 중재 개발이 촉진되고 있습니다. 맞춤형 의료의 추세는 맞춤형 마이크로바이옴 치료제와 잘 맞아떨어집니다. 학계, 산업계, 정부 기관의 협력도 연구개발에 박차를 가하고 과학적 발견을 상업적 제품으로 전환하는 데 박차를 가하고 있습니다. 규제 당국이 마이크로바이옴 치료제의 잠재력을 인식하고 개발 및 승인에 대한 지침을 제공함에 따라 이 분야에 대한 규제 당국의 지원과 투자는 시장 성장에 더욱 기여하고 있습니다.

연구와 혁신에 대한 집중적인 노력으로 장내 세균총이 건강에 미치는 영향에 대한 이해도가 높아지면서 마이크로바이옴 치료제를 위한 탄탄한 기반이 마련되고 있습니다. 캐나다에는 바이오테크와 의약품을 지원하는 규제 환경이 잘 갖춰져 있어 마이크로바이옴에 초점을 맞춘 연구개발에 투자하는 기업이 늘고 있습니다. 또한 벤처캐피털 투자와 정부 자금 증가도 이 연구에 자본을 투입하고 있으며, 2020년 1월 캐나다 정부는 파트너와 함께 중요한 마이크로바이옴 연구에 1,800만 달러를 투자했습니다.

전반적인 건강에서 장 건강과 마이크로바이옴의 중요성에 대한 캐나다 국민들의 인식이 높아지면서 마이크로바이옴 기반 제품에 대한 소비자 수요가 증가하고 있습니다. 또한 캐나다 마이크로바이옴 이니셔티브(Canada Microbiome Initiative, CMI)와 같은 이니셔티브가 광범위하게 시행되고 있기 때문에 캐나다에서는 파트너 및 이해관계자와의 협력이 더욱 용이해졌습니다. 이를 통해 마이크로바이옴 치료제 개발에 연구 노력을 집중할 수 있게 되었습니다. 학계, 생명공학 기업, 의료기관의 협력과 제휴를 통해 연구 및 개발 노력이 가속화되고 있습니다. 또한, 캐나다 기업들은 국제 시장을 개척하여 마이크로바이옴 치료제의 저변을 넓히고 있습니다. 이 모든 요소들이 결합되어 캐나다에서 마이크로바이옴 치료제의 유망한 궤적을 보여주고 있습니다.

ClinicalTrails.com, 질병통제예방센터(CDC), 미국 식품의약국(FDA)은 마이크로바이옴 치료제 시장에 대한 보고서를 작성할 때 참고한 1차 및 이차 정보 중 일부입니다.

북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 기타 유럽
아시아태평양
- 중국
- 일본
- 인도
- 호주
- 한국
- 기타 아시아태평양
중동 및 아프리카
- 사우디아라비아
- 남아프리카공화국
- 아랍에미리트(UAE)
- 기타 중동 및 아프리카
중남미
- 브라질
- 아르헨티나
- 기타 중남미

제11장 마이크로바이옴 치료제 시장 : 업계 상황

마이크로바이옴 치료제 시장 성장 전략
무기적 성장 전략
유기적 성장 전략

제12장 기업 개요

Enterome
Finch Therapeutics Group Inc
Caelus Health
Ferring Pharmaceuticals
Pendulum Therapeutics INC
AOBiome
Seres Therapeutics
Vedanta Biosciences
COST-BRY Pty Ltd(BiomeBank)
YSOPIA Bioscience

제13장 부록

LSH 23.12.18

The microbiome therapeutics market is expected to grow from US$ 375.92 million in 2022 to US$ 813.38 million by 2030; it is anticipated to record a CAGR of 10.1% from 2022 to 2030.

The human microbiome includes all the microorganisms and their related metabolites/products identified in and around the human body. Technological advancement has enabled the examination of the pleiotropic effects of the human gut microbiome in maintaining health and diseases. With the extensive potential of microbes in human health, they hold enormous potential to be used as therapeutics for disease management. Microbiome therapy holds great promise to treat any severe type of disease condition and acts as the potential source to achieve the objective of personalized therapy by overcoming key issues like interpersonal variability and stability in every type of environment. Strategies such as fecal microbiota transplantation (FMT) or probiotics that rely on the administration of exogenous microbes could be used to manage dysbiosis-related disorders.

Potential of Gut Microbiota in Maintaining Human Health drives the growth the Microbiome Therapeutics Market

Microbiome therapeutics are aimed at modifying the gut microbiome by using bacteriophages, bacteriocins, antibiotics, native or synthetic bacteria, or subtractive or modulatory treatment. By offering individualized, harmonized, dependable, and long-lasting therapy, this strategy can overcome the limitations of traditional therapies. The global therapeutics market has demonstrated its enormous economic potential. Studies have shown promising results in using microbiome therapeutics for conditions such as inflammatory bowel disease, obesity, and even mental health disorders. Ongoing research is also exploring the potential of microbiome-based interventions in areas of cancer treatment, diabetes management, and cardiovascular health. Further, the incidence of gastrointestinal illnesses increases with age, and the GI Alliance data from February 2021 estimates that almost 20 million Americans have chronic digestive diseases, and over 62 million Americans receive a diagnosis of gastrointestinal diseases each year. The International Foundation for Gastrointestinal Disorders, Inc. (IFFGD) released statistics showing that GERD prevalence ranges from 18% to 28% in North America, 23% in South America, and 9-26% in Europe. Therefore, in the upcoming years, the increasing frequency of gastrointestinal disorders will fuel the market expansion.

By understanding the intricate relationship between microbiome and disease development, scientists are developing personalized treatments that target the root cause of the problem rather than merely managing symptoms. As knowledge expands and technologies advance, microbiome therapeutics have the potential to become a cornerstone of modern medicine, offering hope for improved health outcomes for individuals affected by a range of diseases.

The growing recognition of the microbiome's importance in human health and disease has encouraged rigorous research and development efforts to further understand the human microbiome and develop microbiome therapeutics. It has helped develop potential therapeutics and identify hindrances. Advancements in technology and research tools have also contributed to growing R&D. Next-generation sequencing and metagenomic analysis have allowed for a more comprehensive and detailed study of the microbiome. These tools enable researchers to identify specific microbial species and their functions, as well as track changes in the microbiome over time. Regulatory agencies, such as the FDA, are also supporting R&D efforts in the field of microbiome therapeutics. The FDA has established guidelines for FMT and has developed interest in advancing the field through regulatory pathways to ensure safety and efficacy. This support from regulatory agencies provides a framework for companies to develop and test microbiome-based therapies, giving investors confidence in the potential success of these treatments. Overall, the increased interest and funding in microbiome therapeutics are driving more research and development efforts. This will lead to a better understanding of the human microbiome and the development of targeted therapies that can modulate the microbiome to improve human health.

The microbiome therapeutics market is divided on the basis of type, application, end user, and geography. The microbiome therapeutics market is divided on the basis of type, application, and end user. Based on type, the microbiome therapeutics market is segmented into therapeutics and procedures. By application, the microbiome therapeutics market is segmented into metabolic disorders and obesity, C. difficile infection, and inflammatory bowel diseases. In terms of end users, the microbiome therapeutics market is classified as hospitals and clinics, ambulatory surgery centers, and home care.

Based on geography, the market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America held the largest market share of the microbiome therapeutics market. North America accounts for a significant market share owing to the growing incidences of C. difficile cases, technological advances, and growing awareness about the importance of gut microbiota. The increasing understanding of the importance of the human microbiome in maintaining health and preventing diseases has led researchers in the US to explore microbiome-based interventions as a promising approach to treat various conditions. Additionally, the dominance of this country in the microbiome therapeutics market is mainly attributed to its well-developed research infrastructure that favors the development of innovative treatments Further, the rising prevalence of chronic diseases such as obesity and inflammatory bowel disease has created a demand for innovative treatments, spurring the development of microbiome therapeutics. Technological advancements in gene sequencing and bioinformatics enable the study and alteration of the microbiome, facilitating the development of personalized microbiome-based interventions. The trend toward personalized medicine aligns well with tailormade microbiome therapeutics. Collaborations between academia, industry, and government organizations are also fueling research and development efforts, accelerating the translation of scientific discoveries into commercial products. Regulatory support and investment in the field further contribute to market growth, as regulatory bodies recognize the potential of microbiome therapeutics and provide guidance for their development and approval.

An emphasis on research and innovation has yielded a significant understanding of the impact of gut microbiota on health, providing a solid foundation for microbiome-based therapeutics. A supportive regulatory environment for biotechnology and pharmaceuticals in Canada has encouraged companies to invest in microbiome-focused research and development. Additionally, increased venture capital investments and government funding have infused capital into this research. In January 2020, the Government of Canada, along with its partners, invested US$ 18 million in crucial microbiome research.

The rising awareness among Canadians about the importance of gut health and microbiome in overall well-being has spurred consumer demand for microbiome-based products. Moreover, the widespread implementation of initiatives such as the Canadian Microbiome Initiative (CMI) makes working with partners and stakeholders easier in Canada. This makes it possible to concentrate research efforts on the development of microbiome therapies. Collaborations and partnerships between academic institutions, biotechnology firms, and healthcare organizations have accelerated research and development efforts. Moreover, Canadian companies are exploring international markets, expanding the reach of microbiome therapeutics. All these factors combined indicate a promising trajectory for microbiome therapeutics in Canada.

ClinicalTrails.com, Centers for Disease Control and Prevention (CDC), and Food and Drug Administration (FDA), are a few key primary and secondary sources referred to while preparing the report on the microbiome therapeutics market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the microbiome therapeutics market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the microbiome therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth market trends and outlook coupled with the factors driving the microbiome therapeutics market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Microbiome Therapeutics Market, by Geography

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Microbiome Therapeutics Market Landscape

4.1 Overview
4.2 PEST Analysis
- 4.2.1 Global PEST Analysis

5. Microbiome Therapeutics Market - Key Industry Dynamics

5.1 Market Drivers:
- 5.1.1 Potential of Gut Microbiota in Maintaining Human Health
- 5.1.2 Inflow of Funds to Ameliorate Microbiome Discovery Pipeline
5.2 Market Restraints
- 5.2.1 High Cost of Development and Production
5.3 Market Opportunities
- 5.3.1 Increasing R&D to Gain Better Understanding of Human Microbiome
5.4 Future Trends
- 5.4.1 Technological Advancement in Human Microbiome Therapeutics
5.5 Impact Analysis:

6. Microbiome Therapeutics Market - Global Market Analysis

6.1 Microbiome Therapeutics Market Revenue (US$ Mn), 2020 - 2030

7. Global Microbiome Therapeutics Market - Revenue and Forecast to 2030 - by Type

7.1 Overview
7.2 Microbiome Therapeutics Market Revenue Share, by Type, 2022 & 2030 (%)
7.3 Procedure
- 7.3.1 Overview
- 7.3.2 Procedure: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Therapeutics
- 7.4.1 Overview
- 7.4.2 Therapeutics: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  - 7.4.2.1 Global: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)

8. Global Microbiome Therapeutics Market - Revenue and Forecast to 2030 - by Application

8.1 Overview
8.2 Microbiome Therapeutics Market Revenue Share, by Application, 2022 & 2030 (%)
8.3 Metabolic Disorder and Obesity
- 8.3.1 Overview
- 8.3.2 Metabolic Disorder and Obesity: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.4 C. Difficile Infection (CDI)
- 8.4.1 Overview
- 8.4.2 C. Difficile Infection (CDI): Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Inflammatory Bowel Disease
- 8.5.1 Overview
- 8.5.2 Inflammatory Bowel Disease: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.6 Others
- 8.6.1 Overview
- 8.6.2 Others: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

9. Global Microbiome Therapeutics Market - Revenue and Forecast to 2030 - by End User

9.1 Overview
9.2 Microbiome Therapeutics Market Revenue Share, by End User, 2022 & 2030 (%)
9.3 Hospitals and Clinics
- 9.3.1 Overview
- 9.3.2 Hospitals and Clinics: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Ambulatory Surgical Centers
- 9.4.1 Overview
- 9.4.2 Ambulatory Surgical Centers: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9.5 Homecare
- 9.5.1 Overview
- 9.5.2 Homecare: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9.6 Others
- 9.6.1 Overview
- 9.6.2 Others: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10. Microbiome Therapeutics Market - Geographical Analysis

10.1 North America Microbiome Therapeutics Market, Revenue and Forecast To 2030
- 10.1.1 Overview
- 10.1.2 North America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
- 10.1.3 North America: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
  - 10.1.3.1 North America: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
- 10.1.4 North America: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
- 10.1.5 North America: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
- 10.1.6 North America Microbiome Therapeutics Market, by Country
  - 10.1.6.1 US
    - 10.1.6.1.1 Overview
    - 10.1.6.1.2 US Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.6.1.3 US: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
    - 10.1.6.1.3.1 US: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
    - 10.1.6.1.4 US: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
    - 10.1.6.1.5 US: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
  - 10.1.6.2 Canada
    - 10.1.6.2.1 Overview
    - 10.1.6.2.2 Canada Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.6.2.3 Canada: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
    - 10.1.6.2.3.1 Canada: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
    - 10.1.6.2.4 Canada: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
    - 10.1.6.2.5 Canada: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
  - 10.1.6.3 Mexico
    - 10.1.6.3.1 Overview
    - 10.1.6.3.2 Mexico Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.6.3.3 Mexico: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
    - 10.1.6.3.3.1 Mexico: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
    - 10.1.6.3.4 Mexico: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
    - 10.1.6.3.5 Mexico: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
10.2 Europe Microbiome Therapeutics Market, Revenue and Forecast to 2030
- 10.2.1 Overview
- 10.2.2 Europe Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
- 10.2.3 Europe: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
  - 10.2.3.1 Europe: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
- 10.2.4 Europe: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
- 10.2.5 Europe: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
- 10.2.6 Europe Microbiome Therapeutics Market, by Country
  - 10.2.6.1 UK
    - 10.2.6.1.1 Overview
    - 10.2.6.1.2 UK Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.2.6.1.3 UK: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
    - 10.2.6.1.3.1 UK: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
    - 10.2.6.1.4 UK: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
    - 10.2.6.1.5 UK: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
  - 10.2.6.2 Germany
    - 10.2.6.2.1 Overview
    - 10.2.6.2.2 Germany Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.2.6.2.3 Germany: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
    - 10.2.6.2.3.1 Germany: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
    - 10.2.6.2.4 Germany: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
    - 10.2.6.2.5 Germany: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
  - 10.2.6.3 France
    - 10.2.6.3.1 Overview
    - 10.2.6.3.2 France Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.2.6.3.3 France: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
    - 10.2.6.3.3.1 France: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
    - 10.2.6.3.4 France: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
    - 10.2.6.3.5 France: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
  - 10.2.6.4 Italy
    - 10.2.6.4.1 Overview
    - 10.2.6.4.2 Italy Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.2.6.4.3 Italy: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
    - 10.2.6.4.3.1 Italy: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
    - 10.2.6.4.4 Italy: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
    - 10.2.6.4.5 Italy: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
  - 10.2.6.5 Spain
    - 10.2.6.5.1 Overview
    - 10.2.6.5.2 Spain Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.2.6.5.3 Spain: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
    - 10.2.6.5.3.1 Spain: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
    - 10.2.6.5.4 Spain: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
    - 10.2.6.5.5 Spain: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
  - 10.2.6.7 Rest of Europe
    - 10.2.6.7.1 Overview
    - 10.2.6.7.2 Rest of Europe Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.2.6.7.3 Rest of Europe: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
    - 10.2.6.7.3.1 Rest of Europe: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
    - 10.2.6.7.4 Rest of Europe: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
    - 10.2.6.7.5 Rest of Europe: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
10.3 Asia Pacific Microbiome Therapeutics Market, Revenue and Forecast to 2030
- 10.3.1 Overview
- 10.3.2 Asia Pacific Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
- 10.3.3 Asia Pacific: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
  - 10.3.3.1 Asia Pacific: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
- 10.3.4 Asia Pacific: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
- 10.3.5 Asia Pacific: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
- 10.3.6 Asia Pacific Microbiome Therapeutics Market, by Country
  - 10.3.6.1 China
    - 10.3.6.1.1 Overview
    - 10.3.6.1.2 China Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.6.1.3 China: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
    - 10.3.6.1.3.1 China: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
    - 10.3.6.1.4 China: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
    - 10.3.6.1.5 China: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
  - 10.3.6.2 Japan
    - 10.3.6.2.1 Overview
    - 10.3.6.2.2 Japan Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.6.2.3 Japan: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
    - 10.3.6.2.3.1 Japan: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
    - 10.3.6.2.4 Japan: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
    - 10.3.6.2.5 Japan: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
  - 10.3.6.3 India
    - 10.3.6.3.1 Overview
    - 10.3.6.3.2 India Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.6.3.3 India: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
    - 10.3.6.3.3.1 India: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
    - 10.3.6.3.4 India: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
    - 10.3.6.3.5 India: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
  - 10.3.6.4 Australia
    - 10.3.6.4.1 Overview
    - 10.3.6.4.2 Australia Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.6.4.3 Australia: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
    - 10.3.6.4.3.1 Australia: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
    - 10.3.6.4.4 Australia: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
    - 10.3.6.4.5 Australia: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
  - 10.3.6.5 South Korea
    - 10.3.6.5.1 Overview
    - 10.3.6.5.2 South Korea Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.6.5.3 South Korea: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
    - 10.3.6.5.3.1 South Korea: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
    - 10.3.6.5.4 South Korea: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
    - 10.3.6.5.5 South Korea: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
  - 10.3.6.7 Rest of Asia Pacific
    - 10.3.6.7.1 Overview
    - 10.3.6.7.2 Rest of Asia Pacific Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.6.7.3 Rest of Asia Pacific: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
    - 10.3.6.7.3.1 Rest of Asia Pacific: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
    - 10.3.6.7.4 Rest of Asia Pacific: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
    - 10.3.6.7.5 Rest of Asia Pacific: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
10.4 Middle East & Africa Microbiome Therapeutics Market, Revenue and Forecast to 2030
- 10.4.1 Overview
- 10.4.2 Middle East & Africa Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
- 10.4.3 Middle East & Africa: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
  - 10.4.3.1 Middle East & Africa: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
- 10.4.4 Middle East & Africa: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
- 10.4.5 Middle East & Africa: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
  - 10.4.5.1 Middle East & Africa Microbiome Therapeutics Market, by Country
  - 10.4.5.2 Saudi Arabia
    - 10.4.5.2.1 Overview
    - 10.4.5.2.2 Saudi Arabia Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.4.5.2.3 Saudi Arabia: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
    - 10.4.5.2.3.1 Saudi Arabia: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
    - 10.4.5.2.4 Saudi Arabia: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
    - 10.4.5.2.5 Saudi Arabia: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
  - 10.4.5.3 South Africa
    - 10.4.5.3.1 Overview
    - 10.4.5.3.2 South Africa Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.4.5.3.3 South Africa: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
    - 10.4.5.3.3.1 South Africa: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
    - 10.4.5.3.4 South Africa: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
    - 10.4.5.3.5 South Africa: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
  - 10.4.5.4 UAE
    - 10.4.5.4.1 Overview
    - 10.4.5.4.2 UAE Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.4.5.4.3 UAE: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
    - 10.4.5.4.3.1 UAE: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
    - 10.4.5.4.4 UAE: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
    - 10.4.5.4.5 UAE: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
  - 10.4.5.5 Rest of Middle East Africa
    - 10.4.5.5.1 Overview
    - 10.4.5.5.2 Rest of Middle East Africa Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.4.5.5.3 Rest of Middle East Africa: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
    - 10.4.5.5.3.1 Rest of Middle East Africa: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
    - 10.4.5.5.4 Rest of Middle East Africa: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
    - 10.4.5.5.5 Rest of Middle East Africa: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
10.5 South & Central America Microbiome Therapeutics Market, Revenue and Forecast to 2030
- 10.5.1 Overview
- 10.5.2 South & Central America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
- 10.5.3 South & Central America: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
  - 10.5.3.1 South & Central America: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
- 10.5.4 South & Central America: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
- 10.5.5 South & Central America: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
- 10.5.6 South & Central America Microbiome Therapeutics Market, by Country
  - 10.5.6.1 Brazil
    - 10.5.6.1.1 Overview
    - 10.5.6.1.2 Brazil Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.5.6.1.3 Brazil: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
    - 10.5.6.1.3.1 Brazil: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
    - 10.5.6.1.4 Brazil: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
    - 10.5.6.1.5 Brazil: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
  - 10.5.6.2 Argentina
    - 10.5.6.2.1 Overview
    - 10.5.6.2.2 Argentina Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.5.6.2.3 Argentina: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
    - 10.5.6.2.3.1 Argentina: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
    - 10.5.6.2.4 Argentina: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
    - 10.5.6.2.5 Argentina: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
  - 10.5.6.3 Rest of South & Central America
    - 10.5.6.3.1 Overview
    - 10.5.6.3.2 Rest of South & Central America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.5.6.3.3 Rest of South & Central America: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
    - 10.5.6.3.3.1 Rest of South & Central America: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
    - 10.5.6.3.4 Rest of South & Central America: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
    - 10.5.6.3.5 Rest of South & Central America: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)

11. Microbiome Therapeutics Market - Industry Landscape

11.1 Overview
11.2 Growth Strategies in Microbiome Therapeutics Market
11.3 Inorganic Growth Strategies
- 11.3.1 Overview
11.4 Organic Growth Strategies
- 11.4.1 Overview

12. Company Profiles

12.1 Enterome
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Finch Therapeutics Group Inc
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Caelus Health
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Ferring Pharmaceuticals
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Pendulum Therapeutics INC
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 AOBiome
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Seres Therapeutics
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Vedanta Biosciences
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 COST-BRY Pty Ltd (BiomeBank)
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 YSOPIA Bioscience
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments

13. Appendix

13.1 About Us
13.2 Glossary of Terms

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다.

US $ 4,450

￦ 6,438,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,450

￦ 9,332,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,450

￦ 12,226,000

※ 부가세 별도

마이크로바이옴 치료제 시장 규모 및 예측, 세계 및 지역 점유율, 동향, 성장 기회 분석 - 유형, 용도, 최종사용자, 지역별

Microbiome Therapeutics Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis By Type, Application, End User, and Geography

목차

제1장 서론

제2장 주요 요약

제3장 조사 방법

제4장 마이크로바이옴 치료제 시장 구도

제5장 마이크로바이옴 치료제 시장 : 주요 산업 역학

제6장 마이크로바이옴 치료제 시장 : 세계 시장 분석

제7장 세계의 마이크로바이옴 치료제 시장 : 매출과 예측, 유형별(-2030년)

제8장 세계의 마이크로바이옴 치료제 시장 : 매출과 예측, 용도별(-2030년)

제9장 세계의 마이크로바이옴 치료제 시장 : 매출과 예측, 최종사용자별(-2030년)

제10장 마이크로바이옴 치료제 시장 : 지역별 분석